In the multicentre, open-label, randomized, controlled trial IABP-SHOCK II, the previously reported 30-day data demonstrated no early mortality reduction with intra-aortic balloon pump (IABP) use in patients undergoing early revascularization for myocardial infarction complicated by cardiogenic shock. The 6-month and 12-month follow-up data have now also been reported. Similarly to the 30-day findings, no mortality reduction was found with IABP use at 6 months (48.7% for IABP use vs 49.2% for control group; relative risk 0.99, 95% CI 0.85–1.16, P = 0.91) or at 12 months (51.8% for IABP use vs 51.4% for control group; relative risk 1.01, 95% CI 0.86–1.18, P = 0.91). These findings contrast with those of other (smaller) studies, which showed reduced mortality only at extended follow-up.
References
Thiele, H. et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet 10.1016/S0140-6736(13)61783-3
Rights and permissions
About this article
Cite this article
Extended follow-up in IABP-SHOCK II shows no reduction in all-cause mortality with IABP. Nat Rev Cardiol 10, 617 (2013). https://doi.org/10.1038/nrcardio.2013.149
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2013.149
